$0.61
4.12%
NYSE, Jun 28, 10:10 pm CET
ISIN
US9286611077
Symbol
VNRX
Sector

VolitionRX Share price

$0.61
-0.08 11.03% 1M
-0.06 8.33% 6M
-0.11 15.62% YTD
-0.85 58.28% 1Y
-2.78 82.10% 3Y
-2.54 80.73% 5Y
-0.93 60.46% 10Y
NYSE, Closing price Fri, Jun 28 2024
ISIN
US9286611077
Symbol
VNRX
Sector

Key figures

Market capitalization $50.16m
Enterprise Value $42.93m
PER (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 53.66
P/S ratio (TTM) P/S ratio 62.70
P/B ratio (TTM) P/B ratio negative
Sales growth (TTM) Sales growth 133.06%
Turnover (TTM) Turnover $800.00k
EBIT (operating result TTM) EBIT $-35.33m
Free cash flow (TTM) Free cash flow $-18.42m
Cash position $11.77m
EPS (TTM) EPS $-0.46
P/E ratio expected negative
P/S ratio expected 17.45
EV/Sales expected 14.94
Short interest 0.79%
Show more

Is VolitionRX a top scorer stock according to the dividend, high growth investing or Leverman strategy?

As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.

VolitionRX Share analysis

Unlock scores for free

Analyst opinions

4 Analysts have issued a VolitionRX forecast:

3x Buy
75%
1x Hold
25%

Analyst opinions

4 Analysts have issued a VolitionRX forecast:

Buy
75%
Hold
25%

Financial data from VolitionRX

Profit and loss account P&L | Balance sheet | Cash flow


Quarter TTM Annually
Mar '24
+/-
%
0.80 0.80
135% 135%
100%
- Direct costs 1.40 1.40
-
175%
-0.60 -0.60
-
-75%
- Selling and administrative expenses 15 15
5% 5%
1,905%
- Research and development costs 18 18
21% 21%
2,260%
-34 -34
6% 6%
-4,241%
- Depreciation and amortization 1.40 1.40
14% 14%
175%
EBIT (operating result) EBIT -35 -35
7% 7%
-4,416%
Net profit -35 -35
11% 11%
-4,364%

Figures in millions USD.

Don't miss a thing! We will send you all news about the VolitionRX share directly to your mailbox free of charge.

If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.

VolitionRX Share News

Neutral
PRNewsWire
3 days ago
HENDERSON, Nev. , June 27, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a mid-year review to stockholders, ahead of its Annual Meeting of Stockholders to be held on July 2, 2024.
Neutral
Accesswire
16 days ago
ORLANDO, FL / ACCESSWIRE / June 14, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) ("Nexalin") and VolitionRX Limited (NYSE American:VNRX) ("Volition") on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, June 15, at 7 p.m. Eastern Time (ET).
Neutral
PRNewsWire
about one month ago
HENDERSON, Nevada , May 29, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that Cameron Reynolds, President and Group Chief Executive Officer, will present and be available for one-to-one meetings at the Jefferies Global Healthcare Conference in New York City. Presentation Details: Date: Wednesday, June 5, 2024 T...
More VolitionRX News

Company profile

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Head office United States
CEO Cameron Reynolds
Employees 110
Founded 1998
Website www.volition.com

Register for free

StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.

The Apple share at a glance with charts, current key figures, news and share analyses.
The best dividend stocks in the dividend top scorer list.
Stock analyses of the best stocks worldwide.
Build wealth now